Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
Status:
Not yet recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time
(FASTEST) Trial is to establish the first treatment for acute spontaneous ICH within a time
window and subgroup of patients that is most likely to benefit. Our central hypothesis is
that rFVIIa, administered within 120 minutes from onset with an identified subgroup of
subjects most likely to benefit, will improve outcomes at 90 days as measured by the modified
Rankin score (mRS) and decrease ongoing bleeding as compared to standard therapy
Phase:
Phase 3
Details
Lead Sponsor:
Joseph Broderick, MD
Collaborators:
National Institute of Neurological Disorders and Stroke (NINDS) Novo Nordisk A/S